GSK's Jem­per­li meets over­all sur­vival pri­ma­ry end­point in PhI­II study

GSK an­nounced that its check­point in­hibitor Jem­per­li added to chemother­a­py helped en­dome­tri­al can­cer pa­tients live longer than chemother­a­py in a Phase III study.

In the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER